Perioperative risks associated with administration of andexanet alfa during emergency cardiac surgery with circulatory arrest.
Ajami GikandiJean M ConnorsChristoph G NabzdykMarco A ZenatiPublished in: Perfusion (2024)
This case report describes the perioperative course of a patient undergoing emergency repair of acute type A thoracic aortic dissection. Andexanet alfa was administered intraoperatively to obtain a dry operative field for right axillary artery exposure and cannulation. Andexanet alfa-induced heparin resistance resulted in cardiopulmonary bypass circuit and pericardial thrombosis requiring more than 400,000 units of unfractionated heparin and antithrombin III to overcome. Postoperatively, excessive chest tube output was observed secondary to protracted heparin rebound requiring continuous dosing of protamine. This case demonstrates the significant challenging perioperative, not just intraoperative, hazards associated with intraoperative andexanet alfa use during emergency cardiac surgery with cardiopulmonary bypass.
Keyphrases
- cardiac surgery
- aortic dissection
- case report
- acute kidney injury
- replacement therapy
- public health
- venous thromboembolism
- emergency department
- patients undergoing
- growth factor
- healthcare
- extracorporeal membrane oxygenation
- drug induced
- lymph node
- high glucose
- liver failure
- emergency medical
- spinal cord
- pulmonary embolism
- diabetic rats
- cell cycle
- smoking cessation
- squamous cell carcinoma
- endothelial cells
- neoadjuvant chemotherapy
- weight gain
- sentinel lymph node
- physical activity
- climate change
- oxidative stress
- spinal cord injury
- radiation therapy
- human health